Oxford Biomedica (LON:OXB) Posts Quarterly Earnings Results

Oxford Biomedica (LON:OXB) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported GBX (30.39) EPS for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%.

Oxford Biomedica Stock Performance

LON:OXB traded down GBX 11.50 during mid-day trading on Wednesday, hitting GBX 481.50. 1,436,216 shares of the stock were exchanged, compared to its average volume of 1,111,019. The firm’s 50-day simple moving average is GBX 515.68 and its 200 day simple moving average is GBX 577.12. The stock has a market capitalization of £582.85 million, a price-to-earnings ratio of -17.89 and a beta of 1.09. Oxford Biomedica has a fifty-two week low of GBX 420 and a fifty-two week high of GBX 952. The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on OXB. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 595 price target on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Jefferies Financial Group restated a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a GBX 900 price target on shares of Oxford Biomedica in a report on Tuesday, September 1st. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of GBX 580.85.

Key Headlines Impacting Oxford Biomedica

Here are the key news stories impacting Oxford Biomedica this week:

• Positive Sentiment: Oxford Biomedica reported 9% first-half revenue growth to £80.2 million and secured a record number of new commercial wins, including 17 new clients. Management maintained its full-year sales outlook, suggesting demand for the company’s cell and gene therapy manufacturing services remains healthy. Oxford Biomedica delivers solid H1 growth, record commercial wins
• Positive Sentiment: The company is advancing a global quality-transformation program using Veeva Quality Cloud. The initiative could improve operational consistency, compliance and scalability as Oxford Biomedica expands its client base. Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud
• Neutral Sentiment: A valuation analysis cited by Yahoo Finance’s earnings preview indicated approximately 35% potential upside based on GF Value. However, this is a model-based estimate rather than a new company catalyst and may carry limited weight while earnings remain negative. Earnings To Watch: Oxford BioMedica PLC
• Negative Sentiment: Quarterly earnings were a loss of GBX30.39 per share, while the company reported a negative 17.85% net margin and negative 48.56% return on equity. Reports also said the first-half loss widened, highlighting pressure on cash generation and the path to profitability. Oxford Biomedica reiterates sales outlook but half-year loss widens

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.